Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Interest & Investment Income (2016 - 2023)

Historic Interest & Investment Income for Gyre Therapeutics (GYRE) over the last 15 years, with Q3 2023 value amounting to $47000.0.

  • Gyre Therapeutics' Interest & Investment Income fell 8333.33% to $47000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $384000.0, marking a year-over-year decrease of 3056.06%. This contributed to the annual value of $717000.0 for FY2022, which is 173846.15% up from last year.
  • Gyre Therapeutics' Interest & Investment Income amounted to $47000.0 in Q3 2023, which was down 8333.33% from $73000.0 recorded in Q2 2023.
  • Gyre Therapeutics' Interest & Investment Income's 5-year high stood at $1.0 million during Q1 2020, with a 5-year trough of -$66000.0 in Q4 2020.
  • In the last 5 years, Gyre Therapeutics' Interest & Investment Income had a median value of $85000.0 in 2020 and averaged $159750.0.
  • In the last 5 years, Gyre Therapeutics' Interest & Investment Income crashed by 11238.94% in 2021 and then surged by 410000.0% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Interest & Investment Income (Quarter) stood at $489000.0 in 2019, then crashed by 113.5% to -$66000.0 in 2020, then skyrocketed by 106.06% to $4000.0 in 2021, then skyrocketed by 4100.0% to $168000.0 in 2022, then plummeted by 72.02% to $47000.0 in 2023.
  • Its Interest & Investment Income was $47000.0 in Q3 2023, compared to $73000.0 in Q2 2023 and $96000.0 in Q1 2023.